弥漫性大B细胞淋巴瘤肿瘤免疫架构的单细胞空间分析
本研究对33例弥漫性大B细胞淋巴瘤(DLBCL)应用成像质谱流式技术(IMC)刻画肿瘤与免疫细胞架构,并与细胞起源、基因突变及化疗反应等临床病理特征关联;同时与霍奇金淋巴瘤IMC数据比较PD-L1、PD-1、TIM-3表达差异,并在DLBCL拓扑结构内识别免疫激活、免疫抑制和免疫排斥的肿瘤中心亚区。
要点
- 对33例DLBCL行IMC分析,将肿瘤与免疫细胞架构与细胞起源、基因突变和化疗反应关联。
- 与霍奇金淋巴瘤IMC数据比较,观察到PD-L1、PD-1和TIM-3表达差异。
- 空间分析识别CXCR3等与免疫细胞穿透免疫沙漠区域相关的标志物。
核心结论
- DLBCL并非组织病理学上单调一致,而是具有复杂的肿瘤架构,肿瘤拓扑结构的变化可与临床相关特征关联。
- 该分析识别出TIM-3、CCR4和CXCR3等候选生物标志物和治疗靶点,与免疫肿瘤学和细胞治疗的联合治疗策略相关。
研究设计与样本
- 对33例弥漫性大B细胞淋巴瘤(DLBCL)病例应用成像质谱流式技术(IMC)进行肿瘤微环境(TME)多重免疫细胞分析。
- 将结果与霍奇金淋巴瘤的IMC数据进行比较。
- 整合肿瘤突变谱分析、细胞起源分类和TME多重免疫表型分析,在单细胞水平对DLBCL进行空间分析。
主要发现
- 与霍奇金淋巴瘤IMC数据比较,观察到PD-L1、PD-1和TIM-3表达差异。
- 创建了肿瘤细胞的空间分类,并在DLBCL拓扑结构内识别出免疫激活、免疫抑制和免疫排斥的肿瘤中心亚区。
- 空间分析识别出CXCR3等与免疫细胞穿透免疫沙漠区域相关的标志物。
临床怎么用
- 作者指出该分析识别出TIM-3、CCR4和CXCR3等候选生物标志物和治疗靶点,与免疫肿瘤学和细胞治疗的联合治疗策略相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiplexed immune cell profiling of the tumor microenvironment (TME) in cancer has improved our understanding of cancer immunology, but complex spatial analyses of tumor-immune interactions in lymphoma are lacking. Here, we used imaging mass cytometry (IMC) on 33 cases of diffuse large B-cell lymphoma (DLBCL) to characterize tumor and immune cell architecture and correlate it to clinicopathological features such as cell of origin, gene mutations, and responsiveness to chemotherapy. To understand the poor response of DLBCL to immune checkpoint inhibitors (ICI), we compared our results to IMC data from Hodgkin lymphoma, a cancer highly responsive to ICI, and observed differences in the expression of PD-L1, PD-1, and TIM-3. We created a spatial classification of tumor cells and identified tumor-centric subregions of immune activation, immune suppression, and immune exclusion within the topology of DLBCL. Finally, the spatial analysis allowed us to identify markers such as CXCR3, which are associated with penetration of immune cells into immune desert regions, with important implications for engineered cellular therapies. This is the first study to integrate tumor mutational profiling, cell of origin classification, and multiplexed immuno-phenotyping of the TME into a spatial analysis of DLBCL at the single-cell level. We demonstrate that, far from being histopathologically monotonous, DLBCL has a complex tumor architecture, and that changes in tumor topology can be correlated with clinically relevant features. This analysis identifies candidate biomarkers and therapeutic targets such as TIM-3, CCR4, and CXCR3 that are relevant for combination treatment strategies in immuno-oncology and cellular therapies.
引用
- Colombo AR, Hav M, Singh M, et al. Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma. Blood Adv. 2022. PMID: 35675517. doi:10.1182/bloodadvances.2022007493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。